https://openbell.ai/ 2026-09-22T12:47:37.944Z hourly 1.0 https://openbell.ai/support 2026-09-22T12:47:37.944Z monthly 0.7 https://openbell.ai/privacy 2026-09-22T12:47:37.944Z monthly 0.5 https://openbell.ai/terms 2026-09-22T12:47:37.944Z monthly 0.5 https://openbell.ai/feed.json 2026-09-22T12:47:37.944Z hourly 0.8 https://openbell.ai/news/QNME:1790081236215 2026-09-22T12:47:16.215Z daily 0.9 https://cdn.brandfetch.io/QNME/w/400/h/400?c=1idopYfmtR7ZKg8QMud Quanome Technologies shares are trading higher after the company announced it entered into a Purchase and Sale Agreement and related purchase order with Compal Electronics for the purchase of 32 GPU server units. openbell Financial News https://openbell.ai/news/ITRI:1790081208109 2026-09-22T12:46:48.109Z daily 0.9 https://cdn.brandfetch.io/ITRI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Itron, Crytica Security Collaborate Over Cyber Threat Detection, Operational Visibility Itron, Inc. (NASDAQ: ITRI) has entered into a strategic technology collaboration with Crytica Security aimed at enhancing cyber threat detection and operational visibility within its intelligent grid-edge infrastructure. This partnership is expected to improve the security measures for Itron's energy and water management solutions. https://openbell.ai/news/DAR:1790081196146 2026-09-22T12:46:36.146Z daily 0.9 https://cdn.brandfetch.io/DAR/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on Darling Ingredients, Raises Price Target to $88 UBS analyst Manav Gupta has maintained a 'Buy' rating on Darling Ingredients (NYSE: DAR) and increased the price target from $78 to $88. This adjustment reflects a positive outlook for the company's performance in the market. https://openbell.ai/news/CMPX:1790081152687 2026-09-22T12:45:52.687Z daily 0.9 https://cdn.brandfetch.io/CMPX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Compass Therapeutics shares are trading lower after the company announced that the FDA recommended it conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer openbell Financial News https://openbell.ai/news/ALK:1790081142551 2026-09-22T12:45:42.551Z daily 0.9 https://cdn.brandfetch.io/ALK/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on Alaska Air Group, Raises Price Target to $54 UBS analyst Atul Maheswari has maintained a 'Buy' rating on Alaska Air Group (NYSE: ALK) and increased the price target from $52 to $54. This adjustment reflects a positive outlook for the company in the market. https://openbell.ai/news/SOFI:1790081108392 2026-09-22T12:45:08.392Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Los-Angeles--California---July-6-2025-So.jpg?width=250&height=187 Buying SOFI Is Like Buying 'AMD or Nvidia' at the Bottom: Strategists Highlight Bold Bull Case for SoFi Technologies Analysts on 'The Deep End' podcast presented a bullish case for SoFi Technologies Inc. (NASDAQ: SOFI), comparing its current valuation to that of AMD and Nvidia at their cyclical lows. SoFi is projected to achieve 30% revenue growth and 40% earnings per share growth over the next three years, despite its stock being down approximately 43% over the past year. The company has expanded to 16 million members and over $45 billion in deposits, with a resilient credit book indicated by a 90-day delinquency rate of 0.40%. As of the latest trading session, SOFI stock rose about 5.95% to $17.98 premarket. https://openbell.ai/news/CXT:1790081091760 2026-09-22T12:44:51.760Z daily 0.9 https://cdn.brandfetch.io/CXT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Crane NXT shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a $60 price target. openbell Financial News https://openbell.ai/news/PSKY:1790080974601 2026-09-22T12:42:54.601Z daily 0.9 https://cdn.brandfetch.io/PSKY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Paramount Skydance shares are trading higher after the company announced the extension of expiration dates of previously announced exchange offers and tender offers on the heels of the settlement of the antitrust lawsuit that delayed the Warner Bros Discovery acquisition. Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $10 to $11.5. openbell Financial News https://openbell.ai/news/SPY:1790080958728 2026-09-22T12:42:38.728Z daily 0.9 https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Redbook Retail Sales Index Up 7.6% YoY For Week Ended 9/19/26 openbell Financial News https://openbell.ai/news/IONQ:1790080948159 2026-09-22T12:42:28.159Z daily 0.9 https://cdn.brandfetch.io/IONQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wedbush Reiterates Outperform on IonQ, Maintains $75 Price Target Wedbush analyst Matt Bryson has reiterated an 'Outperform' rating on IonQ (NYSE: IONQ) and has maintained a price target of $75 for the stock. This reaffirms the firm's positive outlook on IonQ's performance in the market. https://openbell.ai/news/ONMD:1790080878462 2026-09-22T12:41:18.462Z daily 0.9 https://cdn.brandfetch.io/ONMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud OneMedNet Collaborates With Atropos Health To Integrate Its Regulatory Decision-Grade Data To Atropos' Platform OneMedNet Corporation (NASDAQ: ONMD) has entered into a multi-year strategic partnership with Atropos Health to integrate its regulatory decision-grade, AI-driven Real-World Data into Atropos' platform. This collaboration is expected to enhance Atropos' customer offerings and contribute to OneMedNet's Annual Recurring Revenue (ARR) through a fee arrangement. https://openbell.ai/news/DAVA:1790080860864 2026-09-22T12:41:00.864Z daily 0.9 https://cdn.brandfetch.io/DAVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud William Blair Downgrades Endava to Underperform William Blair analyst Maggie Nolan has downgraded Endava (NYSE: DAVA) from Market Perform to Underperform. This change reflects a negative outlook on the company's performance in the market. https://openbell.ai/news/CME:1790080855052 2026-09-22T12:40:55.052Z daily 0.9 https://cdn.brandfetch.io/CME/w/400/h/400?c=1idopYfmtR7ZKg8QMud CME Group To Launch Bitcoin Cash And Uniswap Futures On October 19, Pending Regulatory Review. CME Group plans to launch Bitcoin Cash and Uniswap futures on October 19, pending regulatory review, as part of its expansion in the cryptocurrency market. The new offerings will include larger and Micro-sized contracts for both Bitcoin Cash (250 BCH and 25 BCH) and Uniswap (10,000 UNI and 1,000 UNI) futures, responding to increased client demand for institutional-grade risk management tools. https://openbell.ai/news/YSWY:1790080788987 2026-09-22T12:39:48.987Z daily 0.9 https://cdn.brandfetch.io/YSWY/w/400/h/400?c=1idopYfmtR7ZKg8QMud William Blair Initiates Coverage On Yesway with Outperform Rating William Blair analyst Philip Blee has initiated coverage on Yesway (NASDAQ: YSWY) with an Outperform rating. This marks a significant endorsement for the company as it seeks to enhance its market presence. https://openbell.ai/news/COIN:1790080668885 2026-09-22T12:37:48.885Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Twitter-new-logo-known-as-X-seen-on-smar.jpg?width=250&height=187 Elon Musk's X Launches Cashtag Trading Program With Coinbase, Kraken, Gemini for Bitcoin, Stocks Elon Musk's social media platform X has launched a new 'Trade' option as part of its Cashtag Partner Program, allowing users to transition from discussions about stocks and cryptocurrencies directly to executing trades with brokerages like Coinbase, Kraken, Gemini, and Interactive Brokers. This feature enables users to view asset prices and related conversations on X before trading through the broker's platform. The program aims to connect financial discussions with real-time trading actions, enhancing the user experience for both stocks and cryptocurrencies, including Bitcoin. https://openbell.ai/news/PALI:1790080617393 2026-09-22T12:36:57.393Z daily 0.9 https://cdn.brandfetch.io/PALI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year Palisade Bio, Inc. (NASDAQ: PALI) has received FDA clearance for its Investigational New Drug application for PALI-2108, allowing the company to start the Phase 2 ASCENTRA-CD clinical trial for treating moderate to severe Crohn's disease. The first participant enrollment is expected in the first quarter of next year. https://openbell.ai/news/ADAUSD:1790080527001 2026-09-22T12:35:27.001Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Kaufbeuren--Germany---December-04--2021-.jpg?width=250&height=187 Cardano Joins Solana, XRP in AI Payments Race as ADA Surges 8% Cardano (ADA) has surged 8% in the past 24 hours as it joins the x402 software kit, enabling AI agents to make payments directly in ADA for services. The x402 standard, which transforms the '402 Payment Required' response into a checkout system, allows AI agents to purchase data or computing power without human intervention. Currently, ADA trades at $0.2477, having recently surpassed key Fibonacci retracement levels, with bullish indicators suggesting potential resistance at $0.2563. https://openbell.ai/news/COCH:1790080526807 2026-09-22T12:35:26.807Z daily 0.9 https://cdn.brandfetch.io/COCH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Envoy Medical Granted Two Additional Global Patents Over Its IP Portfolio Envoy Medical Inc. (NASDAQ: COCH) has been granted two additional international patents, increasing its global intellectual property portfolio to a total of 97 patents, which includes 40 U.S. patents and 57 foreign patents. The company also has 26 pending foreign applications and 9 pending U.S. applications. https://openbell.ai/news/COPR:1790080511621 2026-09-22T12:35:11.621Z daily 0.9 https://cdn.brandfetch.io/COPR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Idaho Copper Says U.S. Forest Service Approved Exploration Plan For CuMo Copper Project, Clearing Way For Drilling openbell Financial News https://openbell.ai/news/PLRZ:1790080476273 2026-09-22T12:34:36.273Z daily 0.9 https://cdn.brandfetch.io/PLRZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage Polyrizon Ltd. (NASDAQ: PLRZ) has enrolled its first patient in a U.S. clinical study for NASARIX (PL-14), an investigational Allergy Blocker aimed at treating seasonal allergic rhinitis. This milestone signifies Polyrizon's transition into a clinical-stage company, focusing on the efficacy, safety, and tolerability of its product. The trial marks a key development in the company's strategy to advance its innovative intranasal hydrogels. https://openbell.ai/news/BURU:1790080469991 2026-09-22T12:34:29.991Z daily 0.9 https://cdn.brandfetch.io/BURU/w/400/h/400?c=1idopYfmtR7ZKg8QMud NUBURU Says No Additional Capital Raise Needed To Close Acquisition Of 70% Of Tekne, Targets First Week Of October openbell Financial News https://openbell.ai/news/QNRX:1790080421666 2026-09-22T12:33:41.666Z daily 0.9 https://cdn.brandfetch.io/QNRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Quoin Pharmaceuticals Says FDA Granted Fast Track Designation To QRX003 For Peeling Skin Syndrome openbell Financial News https://openbell.ai/news/SABS:1790080388980 2026-09-22T12:33:08.980Z daily 0.9 https://cdn.brandfetch.io/SABS/w/400/h/400?c=1idopYfmtR7ZKg8QMud SAB Biotherapeutics To Present SAB-142 Phase 1 Data In Type 1 Diabetes At EASD Meeting September 28-30 openbell Financial News https://openbell.ai/news/CMPX:1790080340703 2026-09-22T12:32:20.703Z daily 0.9 https://cdn.brandfetch.io/CMPX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Compass Therapeutics Says FDA Recommended Survival Benefit Trial Before Tovecimig Approval Filing In Biliary Tract Cancer; Company Says New Trial Not Warranted openbell Financial News https://openbell.ai/news/ZEO:1790080318682 2026-09-22T12:31:58.682Z daily 0.9 https://cdn.brandfetch.io/ZEO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zeo Energy Inks Agreement With Ewyze To Partner On Development Of Integrated Off-Grid Power And Data Center Infrastructure Zeo Energy Corp. (Nasdaq: ZEO) has signed an agreement with Ewyze Corp. to collaborate on developing integrated off-grid power and data center infrastructure. The partnership will target opportunities primarily in the United States and select international markets where conditions are favorable. https://openbell.ai/news/SOFI:1790080305371 2026-09-22T12:31:45.371Z daily 0.9 https://cdn.brandfetch.io/SOFI/w/400/h/400?c=1idopYfmtR7ZKg8QMud SoFi Technologies shares are trading higher after the company and Mastercard announced the launch of stablecoin settlement. openbell Financial News https://openbell.ai/news/YOLO:1790080279935 2026-09-22T12:31:19.935Z daily 0.9 https://cdn.brandfetch.io/YOLO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $YOLO The main sentiment is bearish, with users expressing frustration over missed opportunities and the anticipated market dip that has yet to materialize. The key theme revolves around traders' dissatisfaction with current gains and their eagerness for more significant returns. https://openbell.ai/news/AMD:1790080278511 2026-09-22T12:31:18.511Z daily 0.9 https://cdn.brandfetch.io/AMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $AMD Bullish sentiment surrounds AMD as it reaches a $1 trillion market cap following a five-day stock rally, with users reminiscing about past criticisms of the company. Meanwhile, a user expresses regret for delaying their investment journey until age 24. https://openbell.ai/news/NVDA:1790080272619 2026-09-22T12:31:12.619Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $NVDA Nvidia's CEO dismisses concerns about an AI doomsday, suggesting the narrative is aimed at supporting the company's stock value, reflecting a bullish sentiment. Meanwhile, NScale's IPO filing is generating cautious interest, with investors waiting for significant price movement before committing. A day trader shares a positive outcome from a previously struggling altcoin trade, indicating a neutral sentiment on volatility. https://openbell.ai/news/META:1790080270245 2026-09-22T12:31:10.245Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Social Media Discussion: $META The sentiment on r/wallstreetbets is predominantly bullish regarding Meta, with discussions highlighting its recent price surge from ~$550 to ~$740. Many users reflect on past losses and missed opportunities, while some express frustration over shorting the stock. Overall, there's a mix of excitement and caution among traders. https://openbell.ai/news/VTGN:1790080258428 2026-09-22T12:30:58.428Z daily 0.9 https://cdn.brandfetch.io/VTGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Vistagen Says Fasedienol Well-Tolerated Up To 12 Months In Preliminary Open-Label Extension Of Phase 3 Social Anxiety Trial; Plans FDA Meeting This Quarter On New Phase 3 openbell Financial News https://openbell.ai/news/LEN:1790080213709 2026-09-22T12:30:13.709Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Lennar-Company-Logo-Displayed.jpg?width=250&height=187 Berkshire Hathaway Is Buying Lennar While Analysts Turn More Bearish Berkshire Hathaway has increased its stake in Lennar Corporation, acquiring 2.67 million Class A shares and 75,021 Class B shares between September 17 and September 21, 2026. Lennar reported Q3 adjusted earnings of $1.23 per share, missing the consensus estimate of $1.30, with revenue of $8.05 billion also falling short of the $8.31 billion estimate. Analysts have turned bearish, with several firms lowering their price targets, resulting in a Sell consensus rating and an average target of $78. Despite the news, Lennar shares rose 2.32% to $79.89 in premarket trading. https://openbell.ai/news/OBX:1790080194388 2026-09-22T12:29:54.388Z daily 0.9 https://cdn.brandfetch.io/OBX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32 Leerink Partners has initiated coverage on Obsidian Therapeutics (NASDAQ: OBX) with an Outperform rating. The firm has set a price target of $32 for the company's stock. https://openbell.ai/news/PFE:1790080118394 2026-09-22T12:28:38.394Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Hundreds-Of-Drugs-Listed.jpg?width=250&height=187 Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer Public Citizen revealed through a Freedom of Information Act request that the U.S. government signed separate 'Most Favored Nation' contracts with Pfizer and Eli Lilly under President Trump, raising concerns that these agreements may lead to higher medication costs globally. The organization highlighted that ambiguous provisions could incentivize pharmaceutical companies to increase prices for foreign consumers or halt overseas sales. In premarket trading, Eli Lilly shares fell 1.32% to $1149.47, while Pfizer shares decreased by 0.05% to $27.72. https://openbell.ai/news/BTCUSD:1790080026324 2026-09-22T12:27:06.324Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Sell-the-News-Warning.jpg?width=250&height=187 Bitcoin Just Hit a Seven-Month High. The Analyst Calling the Bottom Expects a Pullback Bitcoin (CRYPTO: BTC) surged 11% over the past week, reaching a seven-month high, with analyst Kevin Capital indicating a 90%-95% probability that Bitcoin's low of approximately $60,000 marked the cycle bottom. Despite this bullish outlook, he anticipates a pullback following the recent breakout, with a target range of $93,000 to $100,000 as the next major resistance. Kevin emphasized the importance of Bitcoin forming higher lows to maintain its bullish structure during potential corrections. https://openbell.ai/news/FLNA:1790079900709 2026-09-22T12:25:00.709Z daily 0.9 https://cdn.brandfetch.io/FLNA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times openbell Financial News https://openbell.ai/news/UBER:1790079854301 2026-09-22T12:24:14.301Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Aachen--Germany-September-2019-Uber-Driv.jpg?width=250&height=187 Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’ On September 16, Uber Technologies, Inc. announced a significant expansion of its Costco delivery service via Uber Eats to 47 states, while also confirming the elimination of 10% of its global workforce, amounting to about 3,300 jobs. In related market activity, Uber shares increased by 0.5% to close at $70.84. Meanwhile, Micron Technology, Inc. saw its shares rise 2.8% to $1,043.96 after RBC Capital maintained an Outperform rating with a $1,500 price target. Natera, Inc. and Datadog, Inc. also experienced stock price increases, with Natera closing at $370.64 and Datadog at $245.05, following positive analyst ratings and price target adjustments. https://openbell.ai/news/PLXS:1790079631713 2026-09-22T12:20:31.713Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Side-View-Of-Concentrated-Crypto-Trader-.jpg?width=250&height=187 This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Keybanc analyst Steve Barger upgraded Plexus Corp (NASDAQ: PLXS) from Sector Weight to Overweight, setting a new price target of $300, up from its previous close of $252.36 on Monday. This upgrade is part of a broader trend where several companies, including Metlife Inc and West Pharmaceutical Services Inc, received positive rating changes from analysts, indicating a bullish sentiment in the market. https://openbell.ai/news/GS:1790079562950 2026-09-22T12:19:22.950Z daily 0.9 https://cdn.brandfetch.io/GS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Goldman Sachs Invests $400M Into Cyera Goldman Sachs has invested $400 million into Cyera as an extension of its Series G funding, led by Evolution Equity. This investment aims to enhance Cyera's AI Security product capabilities and support its expansion in the federal market as well as international growth in EMEA and APAC regions, where there is increasing demand for agent oversight. https://openbell.ai/news/SCNX:1790079415851 2026-09-22T12:16:55.851Z daily 0.9 https://cdn.brandfetch.io/SCNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud SCIENTURE To Provide REZENOPY To Addiction Treatment Centers SCIENTURE has entered into an agreement to provide its product REZENOPY™ to around 2,000 Opioid Treatment Program Clinics and other Addiction Treatment Center Networks in the U.S. This move establishes a dedicated commercial channel for the product. According to IQVIA data, the U.S. naloxone market generated approximately $140 million in annual sales, indicating a significant market opportunity. https://openbell.ai/news/META:1790079255824 2026-09-22T12:14:15.824Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jefferies Maintains Buy on Meta Platforms, Raises Price Target to $875 Jefferies analyst Brent Thill has maintained a 'Buy' rating on Meta Platforms (NASDAQ: META) and raised the price target from $710 to $875. This adjustment reflects an optimistic outlook on the company's performance. https://openbell.ai/news/RKTO:1790079217785 2026-09-22T12:13:37.785Z daily 0.9 https://cdn.brandfetch.io/RKTO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rocket One Agrees To Acquire Tracer Drone Technologies; Financial Terms Not Disclosed Rocket One Inc. (NASDAQ: RKTO) has signed a Membership Interest Purchase Agreement to acquire all membership interests of Tracer Drone Technologies, a New Jersey-based provider of drone services. The financial terms of the acquisition have not been disclosed, and the transaction is subject to customary closing conditions. Following the completion of the deal, Tracer will function as a wholly owned subsidiary of Rocket One. https://openbell.ai/news/IMNN:1790079026714 2026-09-22T12:10:26.714Z daily 0.9 https://cdn.brandfetch.io/IMNN/w/400/h/400?c=1idopYfmtR7ZKg8QMud IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification IMUNON, Inc. announced that the Independent Data Monitoring Committee has recommended the continuation of its Phase 2 minimal residual disease (MRD) study of IMNN-001 without modification, citing no new safety signals. The study, which assesses the safety and tolerability of IMNN-001 in combination with standard chemotherapy and bevacizumab for advanced ovarian cancer, has shown a differentiated safety profile with no observed serious adverse events. This recommendation follows positive preliminary data reported in July, indicating deeper anti-tumor activity and immune activation. https://openbell.ai/news/CXT:1790079017082 2026-09-22T12:10:17.082Z daily 0.9 https://cdn.brandfetch.io/CXT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jefferies Initiates Coverage On Crane NXT with Buy Rating, Announces Price Target of $60 Jefferies analyst Stephen Volkmann has initiated coverage on Crane NXT (NYSE: CXT) with a Buy rating. The firm has set a price target of $60 for the stock. https://openbell.ai/news/RNAZ:1790079008666 2026-09-22T12:10:08.666Z daily 0.9 https://cdn.brandfetch.io/RNAZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has made notable progress in its intellectual property portfolio with the acceptance of a patent application in Australia and the issuance of a Notice of Allowance from the Japan Patent Office for its RNA-based therapeutic platform technologies. These developments are significant for the company's focus on immuno-oncology and RNA treatments for high-risk and advanced cancer. https://openbell.ai/news/TRLV:1790079007729 2026-09-22T12:10:07.729Z daily 0.9 https://cdn.brandfetch.io/TRLV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trulieve Cannabis Announces It Has Been Added To S&P Total Market Index And S&P Completion Index Trulieve Cannabis has been added to the S&P Total Market Index (TMI) and the S&P Completion Index (CI), as well as the sector sub-indices S&P TMI Health Care and S&P CI Health Care. The S&P TMI is a broad equity benchmark that includes a wide range of U.S. companies meeting specific eligibility criteria, while the S&P CI comprises the S&P TMI excluding the S&P 500. https://openbell.ai/news/GME:1790078995328 2026-09-22T12:09:55.328Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/22/Rome--Italy---November-29--2024--Entranc.jpg?width=250&height=187 Why Is GameStop Stock Surging Tuesday? GameStop Corp. stock surged on Tuesday after Chairman and CEO Ryan Cohen purchased 1.15 million shares at an average price of $22.9375, totaling approximately $26.4 million. This acquisition increased Cohen's stake to over 40 million shares and follows a series of insider purchases earlier in the month. GameStop shares were up 4.13% in premarket trading, reaching $23.70, although the stock remains down 15.01% over the past year. https://openbell.ai/news/GRAL:1790078978275 2026-09-22T12:09:38.275Z daily 0.9 https://cdn.brandfetch.io/GRAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Baird Maintains Outperform on GRAIL, Raises Price Target to $118 Baird analyst Catherine Schulte has maintained an 'Outperform' rating on GRAIL (NASDAQ: GRAL) and increased the price target from $96 to $118. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/NUR:1790078968615 2026-09-22T12:09:28.615Z daily 0.9 https://cdn.brandfetch.io/NUR/w/400/h/400?c=1idopYfmtR7ZKg8QMud NuRAN Wireless To Pilot Starlink LEO Satellite Service NuRAN Wireless is set to pilot Starlink's low Earth orbit (LEO) satellite service in Nigeria in collaboration with Infratel. This initiative aims to enhance high-capacity connectivity for rural infrastructure, focusing on faster networks and lower-cost capacity. The pilot is expected to create new AI-ready revenue streams for the company. https://openbell.ai/news/WPC:1790078948809 2026-09-22T12:09:08.809Z daily 0.9 https://cdn.brandfetch.io/WPC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jefferies Initiates Coverage On W.P. Carey with Buy Rating, Announces Price Target of $73 Jefferies analyst Joe Dickstein has initiated coverage on W.P. Carey (NYSE: WPC) with a Buy rating. The firm has set a price target of $73 for the stock.